<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="83933">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02012608</url>
  </required_header>
  <id_info>
    <org_study_id>202253</org_study_id>
    <nct_id>NCT02012608</nct_id>
  </id_info>
  <brief_title>Glutamine for the Prevention of Radiation Toxicity in Subjects Undergoing Breast Conserving Therapy</brief_title>
  <official_title>Glutamine for the Prevention of Radiation Toxicity in Subjects Undergoing Breast</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single-centered, double-blind, two-arm randomized study to determine if oral
      glutamine will reduce radiation toxicity for the subjects undergoing Breast Conserving
      Therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Excessive radiation toxicity as defined by Radiation Therapy Oncology Group (RTOG) Acute scale of radiation-toxicity criteria</measure>
    <time_frame>12 days and 30 days</time_frame>
    <description>The primary efficacy outcome will be excessive toxicity, which will be defined as a score of 2 or higher using the Radiation Therapy Oncology Group (RTOG) Acute scale of radiation-toxicity criteria when scored on either the 12-day or 30-day assessment time.
The RTOG scale ranges from 0-4 with 0 being defined as &quot;no change&quot;.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Glutamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Powdered Glutamine, 10.0 grams by mouth three times a day (TID) for 30 days, so that daily dose is 30 grams per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Powdered Dextrose, 8.33 grams by mouth TID for 30 days, so that daily dose is 25 grams per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glutamine</intervention_name>
    <description>Oral glutamine for subjects undergoing breast conserving therapy</description>
    <arm_group_label>Glutamine</arm_group_label>
    <other_name>Gln</other_name>
    <other_name>Q</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>For subjects undergoing breast conserving therapy</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Dextrose</other_name>
    <other_name>Dextrose monohydrate</other_name>
    <other_name>Sugar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject have been diagnosed with Stage I or II invasive breast cancer

          -  Subject will undergo Accelerated Partial Breast Irradiation (APBI) as part of Breast
             Conserving Therapy (BCT)

          -  Subject is eligible for APBI based on American Society of Therapeutic Radiation
             Oncology (ASTRO) criteria

          -  Subject is 18 years of age or older

          -  Subject is female

        Exclusion Criteria:

          -  History of uncontrolled, clinically significant lung, heart, endocrine, liver, or
             renal disease

          -  Subject has been diagnosed with any other cancer

          -  Subject has a known hypersensitivity reaction to the following: oral glutamine (GLN),
             glutamate, monosodium glutamate (MSG) (i.e., Chinese restaurant syndrome)

          -  Subject has history of collagen vascular disease

          -  Subject has been diagnosed with Diabetes mellitus I or II

          -  Subject has had any prior breast radiation

          -  Subject is pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>V. Suzanne Klimberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yihong Kaufmann, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yihong Kaufmann, PhD</last_name>
    <phone>501-257-4811</phone>
    <email>kaufmannyihong@uams.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>V. Suzanne Klimberg, MD</last_name>
    <phone>501-686-6504</phone>
    <email>klimbergsuzanne@uams.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daisy E Wade, CCRP</last_name>
      <phone>501-686-8274</phone>
      <email>dewade@uams.edu</email>
    </contact>
    <investigator>
      <last_name>V. Suzanne Klimberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yihong Kaufmann, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew E Hardee, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sharp F Malak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 4, 2017</lastchanged_date>
  <firstreceived_date>December 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
